<?xml version="1.0" encoding="UTF-8"?>
<p id="Par17">LDV/SOF is one of the DAAs that inhibit enzymes translated from the NS3/4, NS5A, and NS5B regions. Interstitial lung disease is not indicated in the adverse effect information in the package insert for LDV/SOF, but four cases of interstitial lung disease were reported in the early post-marketing phase vigilance of the product [
 <xref ref-type="bibr" rid="CR8">8</xref>], although the details of these cases are unknown. The Japanese Adverse Drug Event Report database includes 14 reports of interstitial lung disease caused by LDV/SOF from 2015 to 2019.
</p>
